M
1.15
-0.05 (-4.17%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Marker Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-2.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -2.33 |
|
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.42% |
| 机构持股比例 | 36.13% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 554,250 |
| Aisling Capital Management Lp | 30 Jun 2026 | 325,370 |
| Concurrent Investment Advisors, Llc | 30 Jun 2026 | 67,963 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合